Health Care Report

This report analyzes the operations of Glaxo Smith Kline (GSK), a multinational pharmaceutical company, in Australia. It examines the legislative and regulatory frameworks affecting GSK's operations, including political and legal environments. The report also identifies key treaties and conventions impacting GSK's products and services, such as the Madrid Joint Convention and the Australia-UK Joint Relation Agreement on drug misuse. The report concludes by highlighting the importance of strategic frameworks for long-term business relationships and the impact of international agreements on GSK's operations.

Health Care

Table of Contents
Executive Summary.........................................................................................................................3
INTRODUCTION...........................................................................................................................3
MAIN BODY...................................................................................................................................3
1) Identification of MNC company........................................................................................3
2) Identify any legislative regulatory framework/s affecting the MNC.................................4
3) Identification of treaties, conventions or agreements and its impact on............................6
products or services of MNC.................................................................................................6
CONCLUSION................................................................................................................................9
RFERENCES ..................................................................................................................................1
.........................................................................................................................................................2

Executive Summary
This report is majorly based on analysis of industry in context of pharmacy with
some of findings over legal framework or level of environment in which business
operation operates. This is one of a pro-active concept to analyse suitable outcomes of
the business to operate in an effective or developed manner. This report has discussed
about industry of this sector, number of staffs worldwide and Australia and location of
the headquarters. Lastly, discussion has been done on legal frameworks and
environment of nation in which business is operating or regulating. Discussion over
treaties has been undertaken to led common relationships with other nations.
INTRODUCTION
Business operations in a current time is operating with maximum efficiency and
also with pro-active stage of products or services in a productive manner. Also, various
multinational company are operating at an optimised stage to led enhance productivity
or efficiency for its own business operation. In current time zone, organisation needs to
be operates with its increased and develop efforts to enhance business productivity
(Dafny and et. al., 2012). In response, this report will be carry on Glaxo Smith Kline,
which is a British multinational pharma based company headquartered in London, UK.
This research paper will cover industry domain and identification in the Australia. Also,
this report will also contain legal regulatory frameworks along with identification of
treaties, conventions or bilateral agreements that has puts their impact on products or
services.
MAIN BODY
1) Identification of MNC company
In this researcher paper, selected MNC is Glaxo Smith Kline Plc. This is a
pharma based company located in Australia and UK. This majorly operates in Australia
due to its major market and people response. The brief description over this MNC is as
follows:

Industry of the company: Glaxo Smith Kline is one of the world largest
research based pharma firm, that is engaged in discovering, developing and
manufacturing of human health products (Çifçi, 2012). The major strategic objective of
GSK is to enhance level of satisfaction of health care and its context at a greater stage.
An industry of the GSK is highly responded to its market base and its suitability for
longer period of time.
Number of staff in Australia: In Australian region, Glaxo is almost have 17000
workers, out of which 3000 are contingent worker and 6800 are manufacturing based
workers. Most of their employee's are on contract basis (Büyüközkan, 2018). In
Australia, GSK employee's are highly skilled and also regulative to perform their defined
work in an effective or productive manner.
Number staff globally: Glaxo Smith have almost 98000 employee's in their
business line along with developing or building of an employee's chain at a large sector.
They are well-known for their employee retention or utilising their efforts at an optimised
period.
Location of the global headquarters: Glaxo Smith has their for major
headquarters in UK, Australia and US. This pharma based firm's operates with their
efficiency or capability all around a world. This business firm is doing small expansion to
grow operational productivity.
2) Identify any legislative regulatory framework/s affecting the MNC
In context of Australia, business entities which are operating in this region have
set their own statutory framework or regulation while in case of operating into this
region. Brief source of research shows that, in Australia, specific regulatory environment
such as political and legal environment is used to be consist of an entire structure in
which business entity such as Glaxo Smith operates at a greater rate (Chan, 2012). As,
Glaxo Smith is majorly operates in pharma sector in which health care or regulation is
necessary, in that situation, this will be suitable to analyse and also put focus on
regulatory framework or environment at an optimised or greater rate. The analysis of
specific regulative environment is consists of:

Political environment: This environment involves ideology, nationalism, stability
and building international relations at a greater ratio. In every pharma based firm's in
which political scenario plays a significant role to enhance major productivity and also
performance at an optimised period of time (Chong, 2017). In this, ideology and idea
generation of the people is used to manage to generate more effective products in given
point of time. Impact of this regulatory environment is increased domain of challenges in
this sectors.
Legal environment: In this environment, certain international laws are used to
be observe such as FCN(friendship, commerce and navigation), ISO(international
standard organisation) and PCT(patent co-operation treaty) have their own influences or
level of support to protecting pharma regulation to led its operation on an effective zone.
In response to this, there are several implication of these two environment's
which in reality needs to be overcome or take necessary action's in order to overcome
it. In context of Glaxo smith, this level of specific regulatory environment has put
implication of this pharma based firm to take decision into the process of enhancing
operational process. Glaxo has impacts these environment in context such as follows:
Product decisions: Physical, chemical, safety, performance, packaging, labelling
and warranty,
Pricing decision: These specific regulatory environment has its own impacts such
as level of price control, resale price maintenance, price freezes, value added system
and taxation.
Distribution: These impacts involves contracts for agents and distribution, level
of physical distribution and insurances,
Promotion: Advertising codes of practice, product restriction, sales promotion,
and
Market research: Collection, storage and transmission of data.
Along with this, clear and depth knowledge of specific regulatory framework in the
pharma sector is necessary to enhance regulation or proactive functioning on an
optimised level. For this, GSK Plc, various framework is necessary to push this sector to
manage and also enhance both business and operational functioning at an optimised
level. The specific frameworks are under:

Regulatory inspection: An existence of various legal provision on regulatory to
check any kind of informal activities going into pharma industry, so as to stop any kind
of informal work or practices to led development of these process with an effective
results or level of outcomes (Berwick, 2017). This is highly prominent to have inspection
officer, so that proper regulation of work will be managed in this pharma sector.
Inspection officer has been assigned roles and major responsibilities to have check on
material quality & composition.
Import control: Legal provisions are necessary in these context to govern
importation of pharma which are already existed in a current country. In the pharma
industry, control over import is necessary to enhance quality material or raw material
from suppliers to product quality or role to led development of products process in an
effective co-relate manner. In order to utilise this, international drug control program
has been initiates in order to accomplishment product quality or measures at an
effective or profitable level.
Licensing: A major existence of this legal provision for licensing of pharma
manufacturer and distributors such as wholesaler and retailers existed in all countries.
Level of legal provisions requires publication good pharmacy practice guidelines(GPPG)
to maintain flow of pharma regulation in an entire pharma facilities for an entire period
or regulations (Hackbarth, 2012). Relatively lower existence of these provisions does
not necessarily means that GPPG and list of pharma are not provided in that countries.
Major impact: These frameworks are highly necessary to led regulations in
pharma sector at an optimised stage of time. This will be prominent to analyse impact of
these framework in order to enhance growth and also productivity in context of the
pharma sector. These framework's will forces would led GSK to implement to various
policies or procedures in order to enhance functioning at a top most level. This has led
GSK to implement policies and also put their major eye on implementation or focusing
on certain level of laws which are already structured in Australia which has led GSK to
implement certain relevant policies in order to enhance conducting of pharma industry in
an effective or productive manner to generate suitable results. These is high pro-active
to enhance outcomes or goals out of this pharma industry in a profitable manner.

3) Identification of treaties, conventions or agreements and its impact on
products or services of MNC
Pharma industry is currently working on major of providing effective and
productive health care service to the people or human being in an effective or
productive manner. Various nations or countries have comes up with joint agreement or
treaties to rise strategic relationships with other's nation to facilitates pharma sector to
develop at its actual or measurable potential to led development of this industry at an
profitable zone or stage. In context with Australia, entities have comes up with certain
joint treaties with other nations such as UK, Spain, USA etc. There are some examples
of the joint treaties by Australia such as Madrid joint convention on wrong usage of
pharma sector, Joint relation of Australia-UK to protect drugs misuse etc. These are
some examples of some joint treaties or convention, which can be major threat for
Glaxo to operates in international market or and that level (Dafny and et. al., 2012).
These agreements are basically initiates to led pharma to run with greater efficiency and
also efforts to raise business outcomes in given period of time.
Madrid joint convention: This treaty has been initiated to enhance statutory
relationship with Australia, UK and Spain, which are highest utiliser of pharmacy in their
nations at a bigger level. This convention has led mutual understanding between three
nation to led flow and proper regulation over usage of drugs and pharmacy sectorial
regulation for longer period. The impact of this treaty is that, it has limits flow of policies
for limiting the use of pharmacy in three different nations at one point of time. One
nation needs to take approval before flow of pharmacy sector in the Australia.
Joint relation agreement between Australia-UK to protect drugs misuse: This
agreement has comes up with mutual understanding to stop smuggling and transferring
of the Drugs from one country to another. In that, authorities of both countries will take
necessary actions in order to protect so. Securities and also other protective measures
has been taken in this context to led stoppage or non regulation of these entities at a
greater point of time. This treaty was signed in 2016 with filling the annexure to take
suitable actions.
Impacts of Glaxo: This treaty has been initiated to protect pharma industry from
any kind of illegal misuse or de-regulation to protect common interest of the people at a

greater context. This has limits flow of goods or services from one place to another. In
this context, supplies and also flow of funds has been impacts which has led GSK to
make certain rules or policies to protect Glaxo Smith pharmacy item to regulate flow and
supplies of the pharmacy products which is a major impact on operations of the GSK at
a loss proportion (Kim, Y. M., and et. al., 2012Groves, P., and et. al., 2016) The
common reason is also that Glaxo was way behind when structuring policies or
implementing long term relations with others.

CONCLUSION
From the above report, it is concluded that strategic frameworks are necessary to
led long term relationships with other business entities to generate effective
relationships with business entities at a greater period. Strategic environment is one
necessary to enhance term relationship between two business parties to enhance
accomplishment of goals or targets in an effective manner. Industry analysis is heavily
prominent to generate suitable outcomes in order to generate relevant idea or level of
ideology such as on what context analysis will be done for achieving suitable outcomes
in role of enhancing business outcomes in a productive way.

RFERENCES
Books & Journals
Berwick, D. M. and Hackbarth, A. D., 2012. Eliminating waste in US health care. Jama.
307(14). pp.1513-1516.
Chong, A. Y. L. and Chan, F. T., 2012. Structural equation modeling for multi-stage
analysis on Radio Frequency Identification (RFID) diffusion in the health care
industry. Expert Systems with Applications. 39(10). pp.8645-8654.
Büyüközkan, G. and Çifçi, G., 2012. A combined fuzzy AHP and fuzzy TOPSIS based
strategic analysis of electronic service quality in healthcare industry. Expert
systems with applications. 39(3). pp.2341-2354.
Nicolay, C. R., and et. al., 2012. Systematic review of the application of quality
improvement methodologies from the manufacturing industry to surgical
healthcare. British Journal of Surgery. 99(3). pp.324-335.
Dafny, L., and et. al., 2012. Paying a premium on your premium? Consolidation in the
US health insurance industry. American Economic Review. 102(2). pp.1161-85.
Moses, H., and et. al., 2013. The anatomy of health care in the United States. Jama.
310(18). pp.1947-1964.
Groves, P., and et. al., 2016. The'big data'revolution in healthcare: Accelerating value
and innovation.
Kim, Y. M., and et. al., 2012. Knowledge sharing and institutionalism in the healthcare
industry. Journal of Knowledge Management. 16(3). pp.480-494.
Bender, D. and Sartipi, K., 2013, June. HL7 FHIR: An Agile and RESTful approach to
healthcare information exchange. In Proceedings of the 26th IEEE International
Symposium on Computer-Based Medical Systems (pp. 326-331). IEEE.
1